The ability of EGCG to restore the levels of p-STAT3 and Bcl-xL in the cochlear cells, but not in cancer cells, could account for its protection of the cochlea without compromising cisplatin’s chemotherapeutic efficacy. Here, STAT3 is linked to cancer.